HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation

Antiviral Therapy

Volumn 12, Issue 6, 2007, Pages 971-975

  Steel, Alan ^a   Conx, Alison E ^b   Shamji, Mohamed H ^b   John, Laurence ^c   Nelson, Mark ^c   Henderson, Don C ^a,b   Gotch, Frances M ^a   Gazzard, Brian G ^c   Kelleher, Peter ^a,b,c  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIGENS, CD38; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; VIRAL LOAD; VIRUS REPLICATION;

EID: 34848818076     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bofill M, Mocroft A, Lipman M, et al. Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS 1996; 10:827-834.
2. Hazenberg MD, Hamann D, Schuitemaker H, Miedema F. T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat Immunol 2000; 1:285-289.
3. + T-cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol 2004; 173:2410-2418.
4. Grossman Z, Meier-Schellersheim M, Sousa AE, Victorino RM, Paul WE. CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause? Nat Med 2002; 8:319-323.
5. Hazenberg MD, Stuart JW, Otto SA, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000; 95:249-255.
6. Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 2004; 104:942-947.
7. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002; 169:3400-3406.
8. Savarino A, Bottarel F, Malavasi F, Dianzani U. Role of CD38 in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions? AIDS 2000; 14:1079-1089.
9. Bofill M, Borthwick NJ, Simmonds HA. Novel mechanism for the impairment of cell proliferation in HIV-1 infection. Immunol Today 1999; 20:258-261.
10. Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS 2004; 18:981-989.
11. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859-870.
12. Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi JV. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:332-340.
13. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:83-92.
14. Mocroft A, Bofill M, Lipman M, et al. CD8+,CD38+ lymphocyte percent: a useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:158-162.
15. ++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS 2002; 16:589-596.
16. Benito JM, Lopez M, Lozano S, Martinez P, Gonzalez-Lahoz J, Soriano V. CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. AIDS Res Hum Retroviruses 2004; 20:227-233.
17. Biancotto A, Grivel JC, Iglehart SJ, et al. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood 2007; 109:4272-4279.
18. Poles MA, Boscardin WJ, Elliott J, et al. Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals. J Acquir Immune Defic Syndr 2006; 43:65-68.
19. Yerly S, Kaiser L, Perneger TV, et al. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. AIDS 2000; 14:243-249.
20. Schockmel GA, Yerly S, Perrin L. Detection of low HIV-1 RNA levels in plasma. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:179-183.
21. Wellons MF, Ottinger JS, Weinhold KJ, et al. Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapy. J Infect Dis 2001; 183:1522-1525.
22. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371.
23. Marziali M, De Santis W, Carello R, et al. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART. AIDS 2006; 20:2033-2041.
24. Hufert FT, van Lunzen J, Janossy G, et al. Germinal centre CD4+ T cells are an important site of HIV replication in vivo. AIDS 1997; 11:849-857.
25. Popovic M, Tenner-Racz K, Pelser C, et al. Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2005; 102:14807-14812.
26. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immuno-deficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-1543.
27. + T cell activation. J Infect Dis 2005; 192:2142-2146.
28. Chapuis AG, Paolo Rizzardi G, D'Agostino C, et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 2000; 6:762-768.
29. Sankatsing SU, Jurriaans S, van Swieten P, et al. Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. AIDS 2004; 18:1925-1931.
30. Garcia F, Plana M, Arnedo M, et al. Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study. J Acquir Immune Defic Syndr 2004; 36:823-830.